3. Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239-1251. 4. 2021 SMR. 104p. 5. 2021CSCO黑色素瘤...
Health care professionals may find clinical trial results for KEYNOTE-006 (a study in patients with advanced melanoma).
在研究结束时,参加KEYNOTE-006研究的患者有资格过渡到KEYNOTE-587研究,以便长期进行生存、进展随访和开始新的抗癌治疗。共210例参加KEYNOTE-006研究的患者入组KEYNOTE-587研究,其中158例来自KEYNOTE-006的帕博利珠单抗组,52例来自伊匹木单...
Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. However, the optimal duration of anti-PD-1 administration is unknown. We present results from 5 years of follow-up of...
[5]Schadendorf D, Dummer R, Hauschild A, et al.Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.[J]. European Journal of Cancer, 2016,67:46-54. ...
In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4...
KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanomaThe KeyNote Trust-Management System Version 2PL6.1 Keynote lecture : Exercise builds brain health: key roles of growth factor cascades and inflammationThe KeyNote trust management system version2, IETF RFC 2704Adolescent brain...
参考文献 5-Year survival and other long-term outcomes from the KENNOTE-006 study of pembrolizumab for ipilimumab-naïve advanced melanoma[R/OL]. 2019 AACR. 版权声明©2022 Baidu |由 百度智能云 提供计算服务 | 使用百度前必读 | 文库协议 | 网站地图 | 百度营销...
Robert C,Ribas A,Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.[J] .Lancet Oncol. July 22, 2019....
KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma The KeyNote Trust-Management System Version 2 PL6.1 Keynote lecture : Exercise builds brain health: key roles of growth factor cascades and inflammation The KeyNote trust management system version2, IETF RFC 2704 ...